Blood Typing Market Size & Growth Forecast 2027–2036, By Segments (Product & Services, Application, Technique, End Use, Test), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Blood Typing Market size stood at USD 2.5 billion in 2026 and is predicted to grow at a 8.17% CAGR from 2027 to 2036, crossing USD 5.48 billion by 2036. The industry revenue for 2027 is calculated at USD 2.67 billion.

• Base Year Value (2026): USD 2.5 billion
• CAGR (2027-2036): 8.17%
• Forecast Year Value (2036): USD 5.48 billion
• Historical Data Period: 2022-2026
• Largest Region: North America
• Forecast Period: 2027-2036

Blood Typing Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America held a 45.40% market share in 2026, supported by established transfusion infrastructure, extensive laboratory networks, and consistently high testing volumes across healthcare settings.
  • Asia Pacific is projected to grow at an 11.42% CAGR, driven by expanding healthcare access, increasing diagnostic capacity, and broader adoption of blood screening and laboratory modernization initiatives.

• Segment Momentum:

  • Reagents & Consumables held a 68.54% share in 2026 due to continuous test-by-test usage in laboratories and hospitals, creating recurring demand that supports both routine operations and high testing volumes.
  • Organ Transplants are the fastest-growing application because precise donor-recipient compatibility requirements increase reliance on accurate blood typing, making it critical for procedural success and improved patient outcomes.

• Market Expansion Drivers:

  • Rising demand for safe transfusions and organ compatibility driving routine blood typing procedures.
  • Expansion of automated and AI-driven analyzers improving diagnostic accuracy and lab efficiency.
  • Growing transplant and surgical volumes increasing demand for advanced immunohematology testing systems.

• Leading Market Participants:

  Prominent players in the blood typing market include Bio-Rad Laboratories, Inc. (United States), Grifols, S.A. (Spain), Immucor, Inc. (United States), Danaher Corporation (United States), Thermo Fisher Scientific Inc. (United States), Quotient Limited (United Kingdom), BAG Diagnostics GmbH (Germany), DIAGAST SAS (France), Merck KGaA (Germany).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2026 Market Size: USD 2.5 billion
  • 2027 Estimated Market Size: USD 2.67 billion.
  • Projected Market Size: USD 5.48 billion by 2036
  • Growth Forecasts: 8.17% CAGR (2027-2036)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Reagents & Consumables (Product & Services) | Diagnostic Testing (Application) | PCR Based and Microarray Based (Technique) | Diagnostic Laboratories (End Use) | Antibody Screening (Test)
  • Emerging Opportunity Segment: Reagents & Consumables (Product & Services) | Organ Transplants (Application) | Assay Based Techniques (Technique) | Blood Banks (End Use) | HLA Typing (Test)

Market Growth Drivers and Industry Trends

Rising demand for safe transfusions and organ compatibility driving routine blood typing procedures

The growing emphasis on transfusion safety and compatibility assessment is strengthening the need for accurate blood group identification across hospitals, blood banks, and diagnostic laboratories. The blood typing market will benefit from the routine requirement to determine blood group compatibility before transfusions and organ transplantation procedures, helping healthcare professionals reduce the risk of immune-mediated complications. Increasing awareness of patient safety and the need for properly matched blood components are encouraging healthcare facilities to maintain reliable typing capabilities as part of standard transfusion workflows. Broader access to surgical and emergency care also increases the frequency of procedures in which accurate blood group determination is required.

Expansion of automated and AI-driven analyzers improving diagnostic accuracy and lab efficiency

Laboratories are increasingly adopting automated analytical platforms to improve consistency, throughput, and workflow management in immunohematology testing. Within the blood typing market, automated and AI-assisted analyzers can support standardized interpretation of blood grouping and compatibility-related results while reducing dependence on repetitive manual procedures. Intelligent systems can assist laboratory personnel in identifying testing discrepancies, managing large sample volumes, and maintaining more consistent quality control. Integration with laboratory information systems further supports streamlined documentation and result management, allowing diagnostic facilities to improve operational efficiency while maintaining reliable blood typing processes.

Growing transplant and surgical volumes increasing demand for advanced immunohematology testing systems

Expansion in surgical procedures and organ transplantation is creating greater requirements for comprehensive pre-procedure blood compatibility assessment. The blood typing market is supported by the need for advanced immunohematology systems capable of performing accurate blood group testing and supporting compatibility evaluation for patients undergoing complex medical interventions. Transplant procedures require careful matching and immunological assessment, while major surgeries often involve transfusion planning and access to compatible blood products. Increasing clinical complexity is encouraging healthcare institutions to adopt testing systems that can handle diverse samples and provide dependable results within established laboratory workflows.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising demand for safe transfusions and organ compatibility driving routine blood typing procedures	2.20%	High	North America, Europe	High	Near Term
Expansion of automated and AI-driven analyzers improving diagnostic accuracy and lab efficiency	2.00%	High	North America, Asia Pacific	High	Near Term
Growing transplant and surgical volumes increasing demand for advanced immunohematology testing systems	1.70%	High	North America, Europe	High	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America led the blood typing market with a 45.40% share in 2026, supported by advanced transfusion medicine infrastructure, widespread availability of automated diagnostic systems, and established blood banking networks. High standards for transfusion safety encourage healthcare facilities to adopt reliable blood grouping and compatibility testing technologies, while sophisticated laboratory capabilities enable efficient processing and accurate identification of blood types. Continued investment in hospital modernization, laboratory automation, and quality assurance further strengthens regional demand. The growing need for dependable transfusion services across surgical care, emergency medicine, maternal healthcare, and chronic disease management also sustains the adoption of advanced blood typing solutions.

Asia Pacific is the fastest-growing region, driven by expanding healthcare infrastructure, improving access to diagnostic services, and increasing demand for safe blood transfusion practices. Investments in hospitals and clinical laboratories are helping broaden access to modern blood grouping technologies, particularly as healthcare systems strengthen their diagnostic capabilities. Growing awareness of transfusion safety and improvements in blood collection and storage practices are also supporting market adoption. In addition, the expansion of healthcare services into developing urban and semi-urban areas is creating greater demand for standardized blood typing procedures and more efficient laboratory workflows.

Key Country Insights

United States

Transfusion Safety Innovation

The U.S. blood typing market is driven by demand for accurate transfusion management and advanced diagnostic workflows. Healthcare providers in the U.S. are increasing the adoption of automated blood typing systems that improve laboratory efficiency and reduce the risk of incompatibility errors.

Japan

Aging Population Screening Demand

Japan's blood typing market benefits from sustained demand for diagnostic testing associated with an aging population and complex healthcare needs. Medical institutions in Japan are prioritizing efficient blood grouping technologies that support routine screening and transfusion preparedness.

South Korea

Advanced Diagnostic Adoption

South Korea is expanding the use of automated blood typing systems within modernized laboratory networks. Healthcare providers in South Korea are emphasizing rapid and accurate testing capabilities to support growing demand for precision diagnostics and efficient blood management practices.

Germany

Laboratory Automation Integration

Germany emphasizes blood typing technologies that support standardized laboratory processes and high diagnostic precision. Hospitals and blood centers in Germany are integrating automated platforms and digital workflows to improve testing consistency and transfusion safety management.

France

Public Blood Service Support

France maintains a strong focus on blood typing solutions that support organized blood collection and transfusion programs. Healthcare institutions in France are investing in reliable testing technologies that enhance traceability and reinforce national blood safety standards.

Italy

Hospital Testing Modernization

Italy is gradually modernizing hospital laboratory infrastructure to improve blood typing and transfusion workflows. Healthcare facilities in Italy are seeking automated and user-friendly systems that enhance testing efficiency while supporting consistent patient safety practices.

Segment Leadership and Growth Trends

 

Product & Services Segment Analysis: Reagents & Consumables (Largest & Fastest-Growing Segment)

Reagents & consumables led the blood typing market with a 68.54% share in 2026 and also represented the fastest-growing product and services segment. Their essential role in blood grouping, compatibility testing, and routine diagnostic workflows supports consistent demand across healthcare and laboratory settings. Reagents and consumable materials are routinely required for testing procedures, making them closely tied to ongoing diagnostic activity rather than occasional equipment replacement cycles. Increasing emphasis on accurate blood identification, transfusion safety, and standardized laboratory practices further reinforces their importance across blood banks and clinical facilities.

Application Segment Analysis: Diagnostic Testing (Largest Segment) vs Organ Transplants (Fastest-Growing Segment)

Diagnostic testing accounted for the largest share of the blood typing market, reaching 56.91% in 2026. The segment benefits from the routine requirement for accurate blood-group identification in clinical diagnostics, transfusion preparation, and patient management. Greater attention to laboratory accuracy and patient safety continues to support demand for reliable blood typing procedures, while expanding healthcare services sustain the need for efficient diagnostic workflows. The integration of advanced testing methods is also helping laboratories improve consistency and streamline blood-group determination.

Organ transplants are the fastest-growing application, driven by the critical need for precise blood compatibility assessment during transplantation procedures. Accurate blood typing is essential for reducing compatibility risks and supporting appropriate donor-recipient matching, making dependable testing particularly important in transplant-focused care. As transplantation programs become more sophisticated, the need for rapid and reliable pre-transplant evaluation is strengthening demand for blood typing solutions within this application.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Product & Services	Instruments, Reagents & Consumables, Services	Reagents & Consumables	Reagents & Consumables
Application	Blood Transfusions, Organ Transplants, Diagnostic Testing	Diagnostic Testing	Organ Transplants
Technique	PCR Based and Microarray Based, Assay Based Techniques, Massively Parallel Sequencing, Other	PCR Based and Microarray Based	Assay Based Techniques
End Use	Hospitals & Clinics, Diagnostic Laboratories, Blood Banks, Others	Diagnostic Laboratories	Blood Banks
Test	Antibody Screening, HLA Typing, Cross-matching, ABO Blood Tests, Others	Antibody Screening	HLA Typing

Competitive Landscape and Market Positioning

Leading companies in the blood typing market:

1. Bio-Rad Laboratories Inc. (United States)

2. Grifols S.A. (Spain)

3. Immucor Inc. (United States)

4. Danaher Corporation (United States)

5. Thermo Fisher Scientific Inc. (United States)

6. Quotient Limited (United Kingdom)

7. BAG Diagnostics GmbH (Germany)

8. DIAGAST SAS (France)

9. Merck KGaA (Germany)

Diagnostic accuracy improvements are shaping innovation in the blood typing market, particularly through advanced testing methodologies. Automation in laboratory workflows is enhancing speed and reliability of results. Increasing focus on precision diagnostics is strengthening adoption in clinical environments.

Industry Development/News

Company Name	Date	Key Development
Thermo Fisher	May-26	Thermo Fisher launched the Axiom BloodGenomiX Array and accompanying software designed to enhance blood transfusion safety through genomic-based blood typing and compatibility analysis. The solution enables clinical laboratories to detect extended and rare blood groups, as well as HLA and platelet types, within a high-throughput workflow, improving precision in donor-recipient matching and reducing transfusion-related clinical risks.
Bio-Rad Laboratories	Jun-25	Bio-Rad Laboratories completed the acquisition of Stilla Technologies to expand its digital PCR capabilities supporting precision diagnostics in transfusion medicine. The acquisition strengthens Bio-Rad’s molecular testing portfolio and enhances its ability to deliver advanced blood typing and compatibility solutions, reinforcing its position in high-precision laboratory diagnostics and expanding its technological footprint in genomic applications.
Werfen	Mar-25	Werfen consolidated its transfusion diagnostics portfolio by unifying Immucor and related subsidiaries under a single brand structure. This organizational integration aims to streamline operations across more than 30 countries, improve commercial efficiency, and strengthen its competitive positioning in specialized diagnostics, particularly within immunohematology and transfusion medicine workflows.